中危前列腺癌患者初次部分腺体冷冻消融后的五年肿瘤学结局:前瞻性队列研究
该前瞻性队列研究纳入313例经MRI筛选的中危前列腺癌患者,评估初次部分腺体冷冻消融(PPGCA)的5年肿瘤学结局。结果显示5年总体临床显著性前列腺癌(csPCa)无复发率为70%(95%CI 57-84),无失败生存率为89%(95%CI 83-95),无前列腺癌死亡,1例(1%)发生转移。
要点
- 5年总体csPCa无复发率70%(95%CI 57-84),无失败生存率89%(95%CI 83-95)。
- 91例随访≥4.5年者中,1例(1%)转移,15例(16.5%)行全腺体挽救治疗。
- 仅3/91(3.3%)未遵守5年监测方案,方案依从性高。
核心结论
- 初次部分腺体冷冻消融(PPGCA)在中危前列腺癌中观察到非常令人鼓舞的中期肿瘤学结局,且对严格前瞻性方案识别复发性csPCa的依从性非常高。
研究设计与样本
- 前瞻性肿瘤学与功能结局研究,纳入476例接受PPGCA的男性,其中313例为MRI一致的中危前列腺癌且治疗前多参数MRI无野外Gleason分级组≥2、无大体包膜外侵犯或极端尖部病变。
主要发现
- 33例(10.5%)检出csPCa(定义为任何Gleason分级组≥2)。
- 91例有≥4.5年随访数据,平均接受8.9次监测PSA、3.4次MRI和2.0次前列腺活检,无失访。
- 5年野外、野外和总体csPCa无复发率分别为86%(95%CI 78-96)、85%(95%CI 63-94)和70%(95%CI 57-84)。
- 5年无失败生存比例为89%(95%CI 83-95);无前列腺癌死亡,1例(1%)发生转移,15例(16.5%)接受全腺体挽救治疗,15例(16.5%)接受挽救性局灶治疗。
关键数值与推荐
- csPCa定义为任何Gleason分级组≥2疾病。
- 无失败定义为无前列腺癌特异性死亡、无转移性疾病或无需全腺体挽救治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess 5-year oncologic outcomes following primary partial gland cryo-ablation (PPGCA) in intermediate-risk prostate cancer. METHODS: Of 476 men undergoing PPGCA enrolled in our prospective oncologic and functional outcomes study, 313 had magnetic resonance imaging (MRI) concordant intermediate-risk prostate cancer with no out-of-field Gleason grade group ≥2, gross extracapsular extension, or extreme apical disease on pre-treatment multi-parametric MRI. Prostatic-specific antigen was monitored every 6 months, and multi-parametric MRI at 6 to 12, 24, 42, and 60 months. Protocol biopsies at 6-12 months and 24 months were discontinued after interim analysis showing low rates of clinically significant prostate cancer (csPCa) defined as any Gleason grade group ≥2 disease. Freedom-from-failure was defined as no prostate cancer-specific mortality, metastatic disease, or whole-gland salvage treatment. RESULTS: csPCa was detected in 33 (10.5%) subjects. Ninety-one had ≥4.5 years of follow-up data with a mean of 8.9, 3.4, and 2.0 surveillance prostatic-specific antigen tests, MRIs, and prostate biopsies; none were lost to follow-up. At 5 years, rates of freedom-from-recurrence of in-field, out-of-field, and overall csPCa were 86% (95% confidence interval [CI]: 78-96), 85% (95% CI: 63-94), and 70% (95% CI: 57-84). The proportion with freedom-from-failure at 5 years was 89% (95% CI: 83-95). None died from prostate cancer, 1 (1%) developed metastasis, 15 (16.5%) underwent whole-gland salvage treatment, and 15 (16.5%) underwent salvage focal therapy. Only 3 of 91 (3.3%) eligible men were non-compliant with 5-year surveillance protocol. CONCLUSION: Very encouraging intermediate-term oncological outcomes following PPGCA were observed with very high compliance to a rigorous prospective protocol for identifying recurrent csPCa.
引用
- Lepor H, Rapoport E, Tafa M, et al. Five-year Oncologic Outcomes Following Primary Partial Gland Cryo-ablation Prospective Cohort Study of Men With Intermediate-risk Prostate Cancer. Urology. 2024. PMID: 39447880. doi:10.1016/j.urology.2024.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。